KSI-101

DRUG2 trials

Sponsors

Kodiak Sciences Inc

Conditions

Macular Edema Secondary to Inflammation

Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

RecruitingNCT06990399

Kodiak Sciences IncMacular Edema Secondary to Inflammation

Start: 2025-07-30End: 2027-11-01Target: 600Updated: 2026-05-18

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

RecruitingNCT06996080

Kodiak Sciences IncMacular Edema Secondary to Inflammation

Start: 2025-07-16End: 2027-08-01Target: 300Updated: 2026-05-18